Global Xerostomia (Dry Mouth) Therapeutics market cagr 11.9%

Xerostomia (Dry Mouth)

Therapeutics Market

Xerostomia (Dry Mouth) Therapeutics Market

Scope: Industry Analysis, Market Size, Growth, Trends Till 2031

Request Sample Report

Xerostomia (Dry Mouth) Therapeutics Market Size and Growth

The global Xerostomia (Dry Mouth) Therapeutics market is expected to reach a value of $XX billion by 2025, growing at a CAGR of X.X% during the forecast period. Factors driving the market include increasing prevalence of xerostomia, rising geriatric population, and advancements in treatment options. Key players in the market include XXXX and XXXX.

Companies Covered (Covid 19 Impact Covered)

◍ GlaxoSmithKline plc

◍ Church & Dwight, Inc.

◍ Colgate-Palmolive Company

◍ Hikma Pharmaceuticals PLC

◍ Pendopharm

◍ Sun Pharmaceuticals Industries Ltd.

◍ Lupin Pharmaceuticals, Inc.

◍ Pfizer, Inc.

◍ Parnell Pharmaceuticals, Inc.

◍ Acacia Pharma

◍ OraCoat

The competitive landscape of the Xerostomia (Dry Mouth) Therapeutics Market includes companies like GlaxoSmithKline plc, Church & Dwight, Inc., ColgatePalmolive Company, Hikma Pharmaceuticals PLC, Pendopharm, Sun Pharmaceuticals Industries Ltd., Lupin Pharmaceuticals, Inc., Pfizer, Inc., Parnell Pharmaceuticals, Inc., Acacia Pharma, and OraCoat. These companies produce various products for the treatment of dry mouth, such as saliva substitutes, mouth rinses, and prescription medications. Their innovative products and strategic partnerships help to grow the Xerostomia (Dry Mouth) Therapeutics Market.

- GlaxoSmithKline plc reported $33.05 billion in sales revenue

- Colgate-Palmolive Company reported $16.67 billion in sales revenue

- Pfizer, Inc. reported $52.54 billion in sales revenue

Request Sample Report

Market Segmentation

By Application

◍ OTC

◍ Prescription

By Product

◍ Salivary Stimulants

◍ Salivary Substitutes

◍ Dentifrices

Request Sample Report